Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADVAN
NCT07477626Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2026
- Primary completion
- Dec 2033
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Biochemical progression-free survival at 5 years. Started Mar 2026; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07477626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477626.